van der Hulst R W, Weel J F, Verheul S B, Keller J J, ten Kate F J, van der Ende A, Rauws E A, Dankert J, Tytgat G N
Department of Gastroenterology, Academic Medical Center, Amsterdam, Netherlands.
Aliment Pharmacol Ther. 1996 Apr;10(2):165-71. doi: 10.1046/j.1365-2036.1996.715895000.x.
Cure rates of H. pylori infection, using dual therapy with omeprazole and amoxycillin, vary considerably and the efficacy of retreatment with this regimen in the case of initial failure is controversial. Therefore, we conducted a large prospective double-blind randomized trial, studying the efficacy of low vs. high dose omeprazole in dual therapy and of early retreatment with the same regimens.
One hundred and sixty-eight consecutive H. pylori-positive patients, suffering from either peptic ulcer disease or functional dyspepsia, were enrolled. Group I (n = 84) received omeprazole 20 mg b.d. plus amoxycillin 750 mg t.d.s., for 2 weeks. Group II (n = 84) received omeprazole 40 mg t.d.s. plus amoxicillin 750 mg t.d.s., for 2 weeks.
The H. pylori eradication rate was 60.2% in group I and 64.3% in group II (P = 0.59). Cure of H. pylori infection was significantly better in patients with peptic ulcer disease, compared to non-ulcer dyspeptics (P = 0.016). Retreatment, given in 54 patients, was successful in 21.4% patients in group I and in 28% patients in group II (P = 0.58).
High dose of omeprazole has no advantage compared to low dose in terms of eradication efficacy. Early retreatment with the same regimen offers limited improvement in cure rate. Presence of peptic ulcer disease influences cure rates significantly.
使用奥美拉唑和阿莫西林进行双重疗法治疗幽门螺杆菌感染的治愈率差异很大,且该方案在初次治疗失败时再次治疗的疗效存在争议。因此,我们进行了一项大型前瞻性双盲随机试验,研究双重疗法中低剂量与高剂量奥美拉唑的疗效以及相同方案早期再次治疗的疗效。
连续纳入168例幽门螺杆菌阳性患者,这些患者患有消化性溃疡疾病或功能性消化不良。第一组(n = 84)接受每日2次,每次20 mg的奥美拉唑加每日3次,每次750 mg的阿莫西林,疗程为2周。第二组(n = 84)接受每日3次,每次40 mg的奥美拉唑加每日3次,每次750 mg的阿莫西林,疗程为2周。
第一组幽门螺杆菌根除率为60.2%,第二组为64.3%(P = 0.59)。与非溃疡性消化不良患者相比,消化性溃疡疾病患者的幽门螺杆菌感染治愈率显著更高(P = 0.016)。54例患者接受再次治疗,第一组21.4%的患者治疗成功,第二组为28%(P = 0.58)。
就根除疗效而言,高剂量奥美拉唑与低剂量相比没有优势。相同方案早期再次治疗治愈率的提高有限。消化性溃疡疾病的存在对治愈率有显著影响。